View in EDS

Recent trends in biosensors for leukemia diagnosis: A critical overview of electrochemical and optical approaches for clinical applicability.

Saved in:
Bibliographic Details
Title: Recent trends in biosensors for leukemia diagnosis: A critical overview of electrochemical and optical approaches for clinical applicability.
Authors: Oliveira, Léony S.1,2,3 (AUTHOR), Andrade, Cesar A.S.1,2 (AUTHOR), Oliveira, Maria D.L.1,2 (AUTHOR), Zine, Nadia3 (AUTHOR), Elaissari, Abdelhamid3 (AUTHOR), Errachid, Abdelhamid1,3 (AUTHOR) abdelhamid.errachid@univ-lyon1.fr
Source: Trends in Analytical Chemistry: TRAC. Jan2025, Vol. 182, pN.PAG-N.PAG. 1p.
Subjects: Blood cell count, Polymerase chain reaction, Fluorescence in situ hybridization, Hematologic malignancies, Cancer diagnosis
Abstract: Leukemia is a hematopoietic cancer with heterogeneous manifestations. For the initial diagnosis and risk stratification of patients, it is necessary to perform several tests together to delineate the prognosis and appropriate therapy. Initial tests involve the evaluation and detection of leukemic cells with complete blood count and flow cytometry with immunophenotyping. However, for decisive therapy classification, tests such as karyotyping, fluorescent in situ hybridization, and RT-PCR (transcriptase reaction combined with polymerase chain reaction) are indispensable. In view of this, various biosensors have been developed with the aim of addressing some of these limitations. This is because these devices are designed for low-cost, simple, and quickly interpretable detection with accuracy. Thus, this review discusses different strategies, techniques, and tools used in leukemia biosensors as well as the main challenges for the real applicability of bio-devices in diagnostic routines. In this regard, biosensors applied to leukemia have been subdivided into the detection of cells and oncogenes. He electrochemical and optical techniques used as transduction methods are discussed, along with nanostructuring, biomarkers, challenges, and perspectives of these tools. Additionally, general biomarkers of interest and innovative strategies involving the combination of different biomolecules are also discussed. Some challenges encountered include the application of biosensors in miniaturized systems compatible with lab-on-chip technologies, as well as devices capable of addressing the complexity of markers in relation to the molecular heterogeneity present in leukemia cases. [Display omitted] • Biosensors serve as an auxiliary tool in patient risk stratification. • Leukemia biosensors can function as cytosensors, genosensors, and prognostic sensors. • Markers, electrochemical techniques, and optical methods are discussed. • MEMS and microfluidics are applied in multi-transduction systems. • This review analyzes the evolution in the complexity of biosensors. [ABSTRACT FROM AUTHOR]
Copyright of Trends in Analytical Chemistry: TRAC is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:Leukemia is a hematopoietic cancer with heterogeneous manifestations. For the initial diagnosis and risk stratification of patients, it is necessary to perform several tests together to delineate the prognosis and appropriate therapy. Initial tests involve the evaluation and detection of leukemic cells with complete blood count and flow cytometry with immunophenotyping. However, for decisive therapy classification, tests such as karyotyping, fluorescent in situ hybridization, and RT-PCR (transcriptase reaction combined with polymerase chain reaction) are indispensable. In view of this, various biosensors have been developed with the aim of addressing some of these limitations. This is because these devices are designed for low-cost, simple, and quickly interpretable detection with accuracy. Thus, this review discusses different strategies, techniques, and tools used in leukemia biosensors as well as the main challenges for the real applicability of bio-devices in diagnostic routines. In this regard, biosensors applied to leukemia have been subdivided into the detection of cells and oncogenes. He electrochemical and optical techniques used as transduction methods are discussed, along with nanostructuring, biomarkers, challenges, and perspectives of these tools. Additionally, general biomarkers of interest and innovative strategies involving the combination of different biomolecules are also discussed. Some challenges encountered include the application of biosensors in miniaturized systems compatible with lab-on-chip technologies, as well as devices capable of addressing the complexity of markers in relation to the molecular heterogeneity present in leukemia cases. [Display omitted] • Biosensors serve as an auxiliary tool in patient risk stratification. • Leukemia biosensors can function as cytosensors, genosensors, and prognostic sensors. • Markers, electrochemical techniques, and optical methods are discussed. • MEMS and microfluidics are applied in multi-transduction systems. • This review analyzes the evolution in the complexity of biosensors. [ABSTRACT FROM AUTHOR]
ISSN:01659936
DOI:10.1016/j.trac.2024.118063